TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38160917

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg subcutaneously every 2 weeks
Number of subjects: 12301

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 12301
Study: 38161174

Group type: EXPERIMENTAL
Intervention: Feelings of vulnerability
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Absence of fear of dying
Number of subjects: 373
Study: 38162283

Group type: COMPARATOR
Intervention: Community-based delivery of HIV services including testing, antiretroviral therapy, treatment monitoring and adherence support, family planning, syndromic management of STIs, menstrual health management, condoms, and HIV prevention and general health counselling.
Number of subjects: 24
Study: 38162439

Group type: EXPERIMENTAL
Intervention: Myasthenia gravis patients
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1660
Study: 38162453

Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous galcanezumab 300 mg
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 38162451

Group type: EXPERIMENTAL
Intervention: Urine-based DOAC dipstick test
Number of subjects: 23
Study: 38162492

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) + Temozolomide (TMZ)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone (standard treatment)
Number of subjects: 41
Study: 38162801

Group type: EXPERIMENTAL
Intervention: Chiglitazar
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 81
Study: 38162999

Group type: EXPERIMENTAL
Intervention: 1.5 g sustained-release L-arginine 3 times/d (4.5 g/d) for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 32
Study: 38163294

Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking program (16-week duration, 34 individualized 1-hour sessions, progressing from 1 to 3 sessions per week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking program
Number of subjects: 10
Study: 38163317

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) followed by 2-year ibrutinib maintenance (I-M)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (I-M)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ibrutinib retreatment
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Overall treatment (iFCR with 2-year I-M)
Number of subjects: 85
Study: 38163318

Group type: EXPERIMENTAL
Intervention: LMP-TCs (third-party latent membrane protein-specific T cells)
Number of subjects: 15
Study: 38163481

Group type: EXPERIMENTAL
Intervention: VAP-specific bundled diagnostic stewardship intervention (VAP-DSI)
Number of subjects: 0
Study: 38163530

Group type: EXPERIMENTAL
Intervention: Lateral Epicondylitis Band (LEB)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Wrist Extensor Splint (WES)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Education-only (wait-and-see)
Number of subjects: 159
Study: 38163585

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 144 weeks (∼3 years)
Number of subjects: 393
Study: 38163904

Group type: EXPERIMENTAL
Intervention: Needs-based communication skills training for nursing professionals
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 180
Study: 38163912

Group type: EXPERIMENTAL
Intervention: Treatment for soil-transmitted helminth infections (STH)
Number of subjects: 262
Study: 38163943

Group type: EXPERIMENTAL
Intervention: Patients with obstructive sleep apnea who developed major adverse cardiac and cerebrovascular events (n = 115)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Smaller ΔQTc
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Higher preoperative oxygen desaturation index
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: ΔQTc within 24 hours after CABG
Number of subjects: 1007
Study: 38164417

Group type: EXPERIMENTAL
Intervention: PEGylated urate oxidase
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 38164441

Group type: EXPERIMENTAL
Intervention: FUEL intervention consisting of weekly online lectures and individual athlete-centered nutrition counseling every other week for sixteen weeks.
Number of subjects: 0
Study: 38164586

Group type: EXPERIMENTAL
Intervention: Radioligand therapy agent (specific agent not mentioned)
Number of subjects: 0
Study: 38164752

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9336

Group type: COMPARATOR
Intervention: Control (standard blood pressure treatment)
Number of subjects: 9336
Study: 38164757

Group type: EXPERIMENTAL
Intervention: XTX101 monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XTX101 in combination with anti-PD-1 mAb
Number of subjects: 0
Study: 38164982

Group type: EXPERIMENTAL
Intervention: DASH-score
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake from DASH food groups
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake from non-DASH food groups
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake from DASH food groups
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake from non-DASH food groups
Number of subjects: 2195
Study: 38165016

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) treatment combined with zoledronic acid (ZA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (h-HSCT only)
Number of subjects: 26
Study: 38165027

Group type: EXPERIMENTAL
Intervention: m-health tool (pre-programmed tablet with weighing scale and interactive education about HF self-care)
Number of subjects: 71
Study: 38165278

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention, 6 sessions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 70
Study: 38165296

Group type: EXPERIMENTAL
Intervention: Aducanumab
Number of subjects: 1681
Study: 38165324

Group type: EXPERIMENTAL
Intervention: MRI/MRA
Number of subjects: 405

Group type: COMPARATOR
Intervention: CT/CTA
Number of subjects: 405
Study: 38165333

Group type: EXPERIMENTAL
Intervention: IV nipocalimab 5 mg/kg Q4W
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IV nipocalimab 30 mg/kg Q4W
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IV nipocalimab 60 mg/kg Q2W
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IV nipocalimab 60 mg/kg single dose
Number of subjects: 68

Group type: COMPARATOR
Intervention: IV placebo Q2W
Number of subjects: 68
Study: 38165335

Group type: EXPERIMENTAL
Intervention: Nerinetide
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 38165678

Group type: EXPERIMENTAL
Intervention: Compliance with the study protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-control group
Number of subjects: 0
Study: 38165683

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with bevacizumab (Cohort 1A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel without bevacizumab (Cohort 1B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2)
Number of subjects: 25
Study: 38165964

Group type: EXPERIMENTAL
Intervention: TRIMOSH intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 240
Study: 38165970

Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention based on psychological counseling, nutrition, and exercise
Number of subjects: 30
Study: 38166036

Group type: EXPERIMENTAL
Intervention: Well-formulated ketogenic diet (WFKD)
Number of subjects: 20
Study: 38166187

Group type: EXPERIMENTAL
Intervention: Quantum molecular resonance treatment with Rexon-Eye device, once per week for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 38166346

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography-based index (α×LL/MLD)
Number of subjects: 0
Study: 38166598

Group type: EXPERIMENTAL
Intervention: Ketofol (ketamine: propofol 1:4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline 0.9% (Control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Emergence agitation and high-dose opioid consumption
Number of subjects: 120
Study: 38166634

Group type: EXPERIMENTAL
Intervention: SGB with 0.5% ropivacaine (group S)
Number of subjects: 58

Group type: COMPARATOR
Intervention: SGB with 0.9% saline (group N)
Number of subjects: 58
Study: 38166647

Group type: COMPARATOR
Intervention: Regorafenib monotherapy
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Regorafenib combined with immune-checkpoint inhibitors
Number of subjects: 537
Study: 38166676

Group type: EXPERIMENTAL
Intervention: Whole-body head-up tilt sleeping (HUTS) at 6°, 12°, and 18°
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo angle (1°) followed by 6° and 12°
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Whole-body head-up tilt sleeping (HUTS)
Number of subjects: 50
Study: 38166677

Group type: EXPERIMENTAL
Intervention: Participation in Bavarian Research Practice Network (BayFoNet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-participation in Bavarian Research Practice Network (BayFoNet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Facilitators for participation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Barriers for participation
Number of subjects: 20
Study: 38166698

Group type: EXPERIMENTAL
Intervention: Anlotinib alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anlotinib + Bevacizumab (Bev)
Number of subjects: 25
Study: 38166710

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg IV every 12 hours
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cystatin C concentrations
Number of subjects: 22
Study: 38166746

Group type: EXPERIMENTAL
Intervention: Tangible support from lay healthcare supporters (LHSs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Emotional support from mental health professionals (MPs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Follow-up interventions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Integrated mental health care service network
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Community instrumental support
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Caring and non-discriminatory environment
Number of subjects: 17
Study: 38166780

Group type: EXPERIMENTAL
Intervention: Living alone group
Number of subjects: 8307

Group type: COMPARATOR
Intervention: Not living alone group
Number of subjects: 8307
Study: 38166797

Group type: EXPERIMENTAL
Intervention: #LIFEGOALS mobile health intervention
Number of subjects: 279

Group type: COMPARATOR
Intervention: No intervention group
Number of subjects: 279
Study: 38166834

Group type: EXPERIMENTAL
Intervention: Biobased polyester cast
Number of subjects: 100

Group type: COMPARATOR
Intervention: Synthetic fiberglass cast
Number of subjects: 100
Study: 38166851

Group type: EXPERIMENTAL
Intervention: Facing Your Fears-School Based (FYF-SB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Zones of Regulation (ZOR)
Number of subjects: 200
Study: 38166864

Group type: EXPERIMENTAL
Intervention: Harm reduction approach
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Patient-centered communication incorporating the harm reduction model
Number of subjects: 89
Study: 38166894

Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program (virtual, 90 minutes, 8 weeks duration)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program
Number of subjects: 43
Study: 38166913

Group type: EXPERIMENTAL
Intervention: Combined (Acetazolamide plus Rapid-Ripc)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Acetazolamide (twice daily, 2 days)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rapid-Ripc (RIPC four times daily, 3 days)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ripc (RIPC twice daily, 6 days)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study: 38166991

Group type: EXPERIMENTAL
Intervention: Visual estimation by surgeons
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Visual estimation by anesthesiologists
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gravimetric method
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Calculation method (López-Picado's formula)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Spectrophotometric measurement
Number of subjects: 61
Study: 38167019

Group type: EXPERIMENTAL
Intervention: Adalimumab with methotrexate co-treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 28
Study: 38167022

Group type: EXPERIMENTAL
Intervention: Radiomics model consisting of nine radiomic features
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional model consisting of serum β-D-glucan levels
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination of radiomics features and serum β-D-glucan levels
Number of subjects: 140
Study: 38167046

Group type: EXPERIMENTAL
Intervention: BASIS-T implementation strategy
Number of subjects: 276

Group type: COMPARATOR
Intervention: Active Comparison Control (ACC)
Number of subjects: 276
Study: 38167064

Group type: EXPERIMENTAL
Intervention: 5% losartan potassium loaded in ethosomal gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: 10% triamcinolone acetonide (intralesional injections)
Number of subjects: 46
Study: 38167068

Group type: EXPERIMENTAL
Intervention: EVAR with sac embolization (SE) using metal coils
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard EVAR
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EVAR with sac embolization (SE)
Number of subjects: 100
Study: 38167115

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered via continuous intravenous administration for 7 days
Number of subjects: 600

Group type: COMPARATOR
Intervention: Saline (placebo) administered via continuous intravenous administration for 7 days
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 600
Study: 38167175

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham RIC
Number of subjects: 80
Study: 38167178

Group type: EXPERIMENTAL
Intervention: Active tDCS (60 min duration, 2 mA for 10 sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham tDCS (60 min duration, placebo treatment for 10 sessions)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 76
Study: 38167204

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion intervention group receiving four weekly 1-h sessions with induction and hypnosis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Active control group receiving four weekly 1-h sessions of induction and mindfulness
Number of subjects: 90

Group type: COMPARATOR
Intervention: Passive control group without intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 38167206

Group type: EXPERIMENTAL
Intervention: E-cigarettes with basic care counselling
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Nicotine pouches with basic care counselling
Number of subjects: 600

Group type: COMPARATOR
Intervention: Basic care counselling only
Number of subjects: 600
Study: 38167216

Group type: EXPERIMENTAL
Intervention: Mesenteric fixation method (MEFIX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Petersen's defect closure method (CLOSURE)
Number of subjects: 0
Study: 38167251

Group type: EXPERIMENTAL
Intervention: Digital Clock and Recall (DCR)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 706
Study: 38167261

Group type: EXPERIMENTAL
Intervention: Siyakhana intervention (3 days of training in depression and substance use focused on psychoeducation, evidence-based skills, and self-care strategies)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Implementation strategy (social contact with people with lived experience of depression/SU during training and clinical supervision)
Number of subjects: 6
Study: 38167285

Group type: EXPERIMENTAL
Intervention: Contact force of the tracheal tube on the tongue during general anaesthesia in different surgical positions
Number of subjects: 54
Study: 38167315

Group type: EXPERIMENTAL
Intervention: Touch-massage® sessions (15 minutes, once a week for three weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group receiving equivalent amount of quiet time (15 minutes, once a week for three weeks)
Number of subjects: 62
Study: 38167321

Group type: EXPERIMENTAL
Intervention: Oncuria BC multiplex immunoassay
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 38167339

Group type: EXPERIMENTAL
Intervention: 1 week hypofractionated radiotherapy (26 Gy in 5 fractions)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: 2 weeks conventional radiotherapy (34 Gy in 10 fractions)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: 1 week hypofractionated radiotherapy
Number of subjects: 1018

Group type: COMPARATOR
Intervention: 2 weeks conventional radiotherapy
Number of subjects: 1018
Study: 38167483

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38167503

Group type: EXPERIMENTAL
Intervention: Immunotherapy (ipilimumab plus nivolumab) followed by BRAF/MEK inhibition (encorafenib plus binimetinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-week induction course of targeted therapy (encorafenib plus binimetinib) followed by immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy (ipilimumab plus nivolumab)
Number of subjects: 0
Study: 38167540

Group type: EXPERIMENTAL
Intervention: 15-min supine time group
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2-h supine time group
Number of subjects: 120
Study: 38167585

Group type: EXPERIMENTAL
Intervention: 8-week exercise program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 38167647

Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) as part of reduced intensity conditioning (RIC) regimen
Number of subjects: 33
Study: 38167806

Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab and apatinib combined with nab-paclitaxel plus S-1 (CA-SAP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Chemotherapy SAP alone (SAP)
Number of subjects: 104
Study: 38167882

Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) with nivolumab
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bipolar androgen therapy (BAT)
Number of subjects: 45
Study: 38167928

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering (target 110 to <130 mmHg)
Number of subjects: 8206
Study: 38167937

Group type: EXPERIMENTAL
Intervention: Toripalimab plus SOX/XELOX
Number of subjects: 108

Group type: COMPARATOR
Intervention: Chemotherapy (SOX/XELOX)
Number of subjects: 108
Study: 38167960

Group type: EXPERIMENTAL
Intervention: Subscapularis fatty infiltration subgroup of NBPP patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Shoulder rotator muscle strength assessment using isokinetic dynamometer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MRI assessment of subscapularis and infraspinatus muscles
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modified Mallet score
Number of subjects: 16
Study: 38168134

Group type: EXPERIMENTAL
Intervention: GP40141
Number of subjects: 56
Study: 38168442

Group type: EXPERIMENTAL
Intervention: 5% 5-Fluorouracil (5-FU) cream, 2g self-administered intravaginally every other week for eight applications.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5% 5-Fluorouracil (5-FU) cream
Number of subjects: 12
Study: 38168815

Group type: EXPERIMENTAL
Intervention: CAD/CAM group with multistranded Stainless Steel wires
Number of subjects: 75

Group type: COMPARATOR
Intervention: Chairside group with Stainless Steel Ortho-FlexTech wires
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lab group with multistranded wires
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study: 38169391

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) + mindfulness meditation (MBM) with implementation intention (II)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Motivational interviewing (MI)
Number of subjects: 170
Study: 38169423

Group type: EXPERIMENTAL
Intervention: Strength Training followed by Aerobic Training (SAG, n=16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Aerobic Training followed by Strength Training (ASG, n=17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both exercise sequences (SAG and ASG)
Number of subjects: 33
Study: 38169488

Group type: EXPERIMENTAL
Intervention: LPG cookstoves and fuel
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Biomass cookstoves
Number of subjects: 3200
Study: 38169489

Group type: EXPERIMENTAL
Intervention: LPG cookstove with continuous free fuel delivery for 18 months
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Biomass cookstove
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: LPG cookstove
Number of subjects: 3200
Study: 38169574

Group type: EXPERIMENTAL
Intervention: Low-dose QiShen YiQi Dripping Pills (QSYQ)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: High-dose QiShen YiQi Dripping Pills (QSYQ)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 38169630

Group type: EXPERIMENTAL
Intervention: Children during the pandemic community lockdown
Number of subjects: 94

Group type: COMPARATOR
Intervention: Children before the pandemic community lockdown
Number of subjects: 94

Group type: COMPARATOR
Intervention: Children following the pandemic community lockdown
Number of subjects: 94